Perjeta®

Understanding Perjeta®
Perjeta® (pertuzumab) is a prescription medicine indicated, in specific treatment settings and regimens, for certain adults with HER2-positive breast cancer. Perjeta® is indicated for use in combination with trastuzumab and docetaxel for the treatment of adults with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease; in combination with trastuzumab and chemotherapy as neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; and for the adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence. HER2 testing should be performed using FDA-approved tests by laboratories with demonstrated proficiency. Perjeta® is a HER2/neu receptor antagonist administered by intravenous infusion. Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of HER2 and inhibits ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3, and HER4.

How Perjeta® Works:

  • Targets the HER2 receptor: Perjeta® contains pertuzumab, a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of HER2.
  • Inhibits HER2 heterodimerization: Pertuzumab inhibits ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3, and HER4.
  • Inhibits downstream signaling: Pertuzumab inhibits downstream signaling through two major signaling pathways, MAP kinase and phosphoinositide 3-kinase (PI3K).
  • Demonstrates antibody-dependent cellular cytotoxicity (ADCC): Pertuzumab mediates antibody-dependent cellular cytotoxicity (ADCC) in vitro.
Perjeta® (pertuzumab) received its initial U.S. FDA approval in 2012 for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who had not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Since then, Perjeta® has received additional FDA approvals in the neoadjuvant and adjuvant treatment settings for HER2-positive breast cancer.

For more information, please visit the Perjeta® patient website. Speak with your healthcare provider to determine if Perjeta® is the right treatment option for you.

Referral Form:
WHAT IT TREATS:
MANUFACTURER:
Genentech, Inc.
CLASS:
HER2/neu receptor antagonist (monoclonal antibody)
PRESCRIBED BY:
HOW ADMINISTERED:
Intravenous (IV) infusion
FREQUENCY:

Every 3 weeks

Length of infusion:
30 to 60 minutes, depending on dose number and patient tolerability. Initial infusion is typically 90 minutes.

Related drugs